FY09 DOD Lung Cancer Biospecimen Resource Network Award

archived

The LCRP Lung Cancer Biospecimen Resource Network (LCBRN) Award is intended to provide infrastructure support for the development of a lung cancer biospecimen resource that will facilitate the collection, processing, annotation, storage, and distribution of high-quality human lung cancer biospecimens through a collaborative network across multiple institutions. The LCBRN will consist of a Coordinating Center that will also function as a biospecimen resource site and a minimum of two additional Biospecimen Resource Sites that will be jointly responsible for developing the biospecimen resource network for lung cancer research. The Coordinating Center and Biospecimen Resource Sites must submit a single application. It is expected that the Coordinating Center will provide unique resources that may not necessarily be available at each Biospecimen Resource Site and can be leveraged for the LCBRN as a group. The types of lung cancer biospecimens for this proposal may be quite diverse. A list of possible biospecimens may include but are not limited to tumor tissue, matching uninvolved lung parenchyma or airway epithelium, lung exhalant, tissue, blood, sputum, hair, toenails, and bronchoscopic brushings and biopsies. Additional requirements for the LCBRN will be the ability to collect, store, and manage data derived from these biospecimens. LCBRN applicants should possess the ability to derivatize DNA, RNA, and proteins, and also utilize both standard and state-of-the-art technologies (e.g., laser capture microdissection, tissue microarrays) to provide the necessary biospecimen processing for lung cancer research studies. The proposed LCBRN must collect, process, annotate, store, and distribute human lung cancer biospecimens that support two or more of the Areas of Emphasis listed below: • Identification or development of non-invasive or minimally invasive tools to improve the detection of the initial stages of lung cancer. • Identification and development of tools for screening or early detection of lung cancer. Screening may include, but is not limited to, computed tomography scans, X-rays, other imaging, biomarkers, genetics/genomics/proteomics, and assessment of risk factors. • Understanding the molecular mechanisms that lead to clinically significant lung cancer. • Identification of the mechanisms that lead to the development of the various types of lung cancer. • Identification of innovative strategies for prevention and treatment of early lung cancer. • Understanding predictive and prognostic markers to identify responders and non-responders. • Understanding acquired resistance to treatment. See the Program Announcement for the full Funding Opportunity Description.

High